Search
The National Healthcare Security Administration, in collaboration with the National Health Commission, has jointly unveiled the "Several Measures to Support the High-Quality Development of Innovative Drugs." These measures encompass 16 specific initiatives aimed at comprehensively bolstering the R&D, accessibility, utilization, and payment systems for innovative drugs. According to CITIC Securities' analysis, this policy shift will not only propel the high-quality development of China's innovative drugs but also herald a new era of genuine pharmaceutical innovation and internationalization. It is advisable to prioritize strategies centered on innovation, internationalization, autonomy, and the reform of out-of-hospital marketing models, with a keen eye on the burgeoning opportunities in the realm of innovative drugs.
-
C114 Communication Network -
Communication Home
